ISPAD Clinical Practice Guidelines 2024: Editorial
- PMID: 39681103
- PMCID: PMC11854966
- DOI: 10.1159/000543154
ISPAD Clinical Practice Guidelines 2024: Editorial
Conflict of interest statement
F.H.M. received research support from the Canadian Institute for Health Research (CIHR), Physicians Services Incorporated, Heart and Stroke Foundation, Diabetes UK, and Breakthrough Diabetes (formerly JDRF). K.D. received honoraria for participation in the speaker’s bureau of Abbott, Eli Lilly, Medtronic, Novo Nordisk A/S, and Pfizer and advisory board for Medtronic and Novo Nordisk. C.E.S. received speaker honoraria from Medtronic and Eli Lilly and advisory boards for Abbott. M.L.M. and L.P. have no conflicts of interest to declare. L.A.D. received research support from the NIH, JDRF, and the Helmsley Charitable Trust. Her institution has received research support from Dompe, Lilly, Mannkind, Medtronic, Provention Bio, Sanofi, and Zealand. She has consulted for Abata, Tandem, Biomea Fusion, and Vertex. She also received payment from Sanofi for a CME talk (content independently developed by L.A.D.).
Publication types
LinkOut - more resources
Full Text Sources
